Centene’s Drug Pricing Battles Force It To Restructure PBM Business
The drugmaker said it will restructure its pharmacy-benefits management business following claims by several states it had inflated drug costs and cost taxpayers money. Texas' $290 million opioid settlement and Rafael Pharma's pancreatic cancer trial are also in the news.